Method for providing radiopaque nitinol alloys for medical devices

Abstract
A radiopaque nitinol medical device such as a stent for use with or implantation in a body lumen is disclosed. The stent is made from a superelastic alloy such as nickel-titanium or nitinol, and includes a ternary element selected from the group of chemical elements consisting of iridium, platinum, gold, rhenium, tungsten, palladium, rhodium, tantalum, silver, ruthenium, or hafnium. The added ternary element improves the radiopacity of the nitinol stent comparable to that of a stainless steel stent of the same and strut pattern coated with a thin layer of gold. The nitinol stent has improved radioplacity yet retains its superelastic and shape memory behavior and further maintains a thin strut/wall thickness for high flexibility.
Description
BACKGROUND OF THE INVENTION

present invention generally relates to self-expanding medical devices. More precisely, the present invention relates to self-expanding medical devices made of radiopaque nitinol that can be used in essentially any body lumen. Such devices include stents.


Stents are typically implanted in a body lumen, such as carotid arteries, coronary arteries, peripheral arteries, veins, or other vessels to maintain the patency of the lumen. These devices are frequently used in the treatment of atherosclerotic stenosis in blood vessels especially after percutaneous transluminal angioplasty (PTA) or percutaneous transluminal coronary angioplasty (PTCA) procedures with the intent to reduce the likelihood of restenosis of a vessel. Stents are also used to support a body lumen, tack-up a flap or dissection in a vessel, or in general where the lumen is weak to add support.


During PTCA procedures it is common to use a dilatation catheter to expand a diseased area to open the patient's lumen so that blood flows freely. Despite the beneficial aspects of PTCA procedures and its widespread and accepted use, it has several drawbacks, including the possible development of restenosis and perhaps acute thrombosis and sub-acute closure. This recurrent stenosis has been estimated to occur in seventeen to fifty percent of patients despite the initial PTCA procedure being successful. Restenosis is a complex and not fully understood biological response to injury of a vessel which results in chronic hyperplasia of the neointima. This neointimal hyperplasia is activated by growth factors which are released in response to injury. Acute thrombosis is also a result of vascular injury and requires systemic antithrombotic drugs and possibly thrombolytics as well. This therapy can increase bleeding complications at the catheter insertion site and may result in a longer hospital stay. Sub-acute closure is a result of thrombosis, elastic recoil, and/or vessel dissection.


Several procedures have been developed to combat restenosis and sub-acute or abrupt closure, one of which is the delivery and implanting of an intravascular stent. Stents are widely used throughout the United States and in Europe and other countries. Generally speaking, the stents can take numerous forms. One of the most common is a generally cylindrical, hollow tube that holds open the vascular wall at the area that has been dilated by a dilation catheter. One highly regarded stent used and sold in the United States is known under the tradename ACS Multi-Link Stent, which is made by Advanced Cardiovascular Systems, Inc., Santa Clara, Calif.


In expandable stents that are delivered with expandable catheters, such as balloon catheters, the stents are positioned over the balloon portion of the catheter and are expanded from a reduced diameter to an enlarged diameter greater than or equal to the inner diameter of the arterial wall by inflating the balloon. Stents of this type can be expanded to an enlarged diameter by deforming the stent, by engagement of the stent walls with respect to one another, and by one way engagement of the stent walls together with endothelial growth onto and over the stent.


Examples of intravascular stents can be found in U.S. Pat. No. 5,292,331 (Boneau); U.S. Pat. No. 4,580,568 (Gianturco); U.S. Pat. No. 4,856,516 (Hillstead); U.S. Pat. No. 5,092,877 (Pinchuk); and U.S. Pat. No. 5,514,154 (Lau et al.), which are incorporated herein by reference in their entirety.


The problem with some prior art stents, especially those of the balloon expandable type, is that they are often stiff and inflexible. These balloon expandable type stents are commonly formed from stainless steel alloys and the stents are constructed so that they are expanded beyond their elastic limit. As a result, such stents are permanently deformed by the inflation balloon beyond their elastic limits to hold open a body lumen and thus maintain patency of that body lumen. There are several commercially available balloon expandable stents that are widely used; they are generally implanted in the coronary arteries after a PTCA procedure mentioned earlier.


Stents are often times implanted in vessels that are closer to the surface of the body, such as in the carotid arteries in the neck or in peripheral arteries and veins in the leg. Because these stents are so close to the surface of the body, they are particularly vulnerable to impact forces that can partially or completely collapse the stent and thereby block fluid flow in the vessel. Other forces can impact balloon expandable stents and cause similar partial or total vessel blockage. For instance, under certain conditions, muscle contractions might also cause balloon expandable stents to collapse partially or completely. The collapse occludes the lumen and restricts blood flow in the vessel in which they are implanted.


Since balloon expandable stents are plastically deformed, once collapsed or crushed they remain so, permanently blocking the vessel. Thus, balloon expandable stents under certain conditions might pose an undesirable condition for the patient.


Self-expanding stents as the name implies self-expand through the properties of the material constituting the stent. The inflation force of a balloon catheter is usually not necessary to deploy this kind of stent.


Important applications including those mentioned above have prompted designers to seek out superelastic shape memory alloys to exploit the materials' properties in their self-expanding stents. Examples of applying superelastic nickel-titanium alloys to a self-expanding stent and other medical devices are disclosed in U.S. Pat. Nos. 4,665,906; 5,067,957; 5,190,546; and 5,597,378 to Jervis and U.S. Pat. No. 4,503,569 to Dotter. Another example is disclosed in European Patent Application Publication No. EP0873734A2, entitled “Shape Memory Alloy Stent.” This publication suggests a stent for use in a lumen in a human or animal body having a generally tubular body formed from a shape memory alloy which has been treated so that it exhibits enhanced elastic properties. The publication further suggests use of specified ternary elements in a nickel-titanium alloy to obtain desired engineering characteristics.


Use of a ternary element in a superelastic stent is also shown in, for example, U.S. Pat. No. 5,907,893 to Zadno-Azizi et al. As a general proposition, there have been attempts at adding a ternary element to nickel-titanium alloys as disclosed in, for instance, U.S. Pat. No. 5,885,381 to Mitose et al


Clearly, self-expanding, nickel-titanium stents are useful and valuable to the medical field. But a distinct disadvantage with self-expanding nickel-titanium stents is the fact that they are not sufficiently radiopaque as compared to a comparable structure made from gold or tantalum. For example, radiopacity permits the cardiologist or physician to visualize the procedure involving the stent through use of fluoroscopes or similar radiological equipment. Good radiopacity is therefore a useful feature for self-expanding nickel-titanium stents to have.


Radiopacity can be improved by increasing the strut thickness of the nickel-titanium stent. But increasing strut thickness detrimentally affects the flexibility of the stent, which is a quality necessary for ease of delivery. Another complication is that radiopacity and radial force co-vary with strut thickness. Also, nickel-titanium is difficult to machine and thick struts exacerbates the problem.


Radiopacity can be improved through coating processes such as sputtering, plating, or co-drawing gold or similar heavy metals onto the stent. These processes, however, create complications such as material compatibility, galvanic corrosion, high manufacturing cost, coating adhesion or delamination, biocompatibility, loss of coating integrity following collapse and deployment of the stent, etc.


Radiopacity can also be improved by alloy addition. One specific approach is to alloy the nickel-titanium with a ternary element. What has been needed and heretofore unavailable in the prior art is a superelastic nickel-titanium stent that includes a ternary element to increase radiopacity yet preserves the superelastic qualities of the nitinol.


SUMMARY OF THE INVENTION

The present invention relates to a radiopaque medical device, such as a stent, for use or implantation in a body lumen. In a preferred embodiment, a radiopaque medical device, such as a stent, is constructed from a tubular-shaped body having a thin wall defining a strut pattern; wherein the tubular body includes a superelastic, nickel-titanium alloy, and the alloy further includes a ternary element selected from the group of chemical elements consisting of iridium, platinum, gold, rhenium, tungsten, palladium, rhodium, tantalum, silver, ruthenium, or hafnium. In a preferred embodiment, the stent according to the present invention has 42.8 atomic percent nickel, 49.7 atomic percent titanium, and 7.5 atomic percent platinum.


As a result, the present invention stent is highly radiopaque as compared to an identical structure made of medical grade stainless steel that is coated with a thin layer of gold. From another perspective, for a given stent having a certain level of radiopacity, the present invention stent having identical dimensions and strut pattern has at least a 10 percent reduction in strut thickness yet maintains that same level of radiopacity.


Self-expanding nitinol stents are collapsed (that is, loaded) and then constrained within a delivery system. At the point of delivery, the stent is released (that is, unloaded) and allowed to return to its original diameter. The stent is designed to perform various mechanical functions within the lumen, all of which are based upon the lower unloading plateau stress. Therefore, it is crucial that the ternary element alloyed with the binary nickel-titanium does not diminish the superelastic characteristics of the nickel-titanium.


To achieve the sufficient degree of radiopacity yet maintaining the superelastic engineering properties of a binary nickel-titanium, preferably, the radiopaque stent of the present invention includes platinum whose atomic percent is greater than or equal to 2.5 and less than or equal to 15. In an alternative embodiment, the nickel-titanium is alloyed with palladium whose atomic percent is greater than or equal to 2.5 and less than or equal to 20. With such compositions, the stress-strain hysteresis curve of the present invention radiopaque nitinol alloy closely approximates the idealized stress-strain hysteresis curve of binary nickel-titanium.


The present invention further contemplates a method for providing a radiopaque nitinol stent. In a preferred embodiment, the method entails providing a tubular-shaped body having a thin wall, wherein the body includes a superelastic nickel-titanium alloy and the alloy further includes a ternary element selected from the group of chemical elements consisting of iridium, platinum, gold, rhenium, tungsten, palladium, rhodium, tantalum, silver, ruthenium, or hafnium; forming a strut pattern wherein the stent is highly radiopaque. The step of providing a tubular-shaped body includes melting nickel, titanium, and the ternary element and cooling the mixture to form an alloy ingot, hot forming the alloy ingot, hot or cold forming the alloy ingot into a cylinder, drilling the cylinder to form tubing, cold drawing the tubing, and annealing the tubing.


The present invention of course envisions the minor addition of a quaternary element, for example, iron, to further enhance the alloy's formability or its thermomechanical properties. In short, the presence of elements in addition to the ternary elements cited above is contemplated.


In a preferred embodiment, an austenite finish temperature (Af) of the superelastic alloy in the stent is greater than or equal to zero and less than or equal to 37 degrees C. Also in the preferred embodiment, the ingot after melting includes an austenite finish temperature (Af) of greater than or equal to 0 degrees C. and less than or equal to 40 degrees C. The tubing includes an austenite finish temperature (Af) of greater than or equal to −15 degrees C. and less than or equal to 15 degrees C.


Other features and advantages of the present invention will become more apparent from the following detailed description of the invention when taken in conjunction with the accompanying exemplary drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a side elevational view, partially in section, depicting a stent mounted on a delivery catheter and expanded within a damaged vessel, pressing a damaged vessel lining against the vessel wall.



FIG. 2 is a side elevational view, partially in section, depicting an expanded stent within the vessel after withdrawal of the delivery catheter.



FIG. 3 is an idealized stress-strain hysteresis curve for a superelastic material.



FIG. 4 is a plan view of the flattened strut pattern of an exemplary embodiment superelastic stent.



FIG. 5 is a group of empirical data curves illustrating the highly similar stress-strain relationships among binary nitinol and the nickel-titanium-palladium and nickel-titanium-platinum alloys used in the present invention.





DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a medical device made of radiopaque nitinol. For the sake of illustration, the following exemplary embodiments are directed to stents, although it is understood that the present invention is applicable to other medical devices usable in a body lumen as well.


The stents of the present invention can have virtually any configuration that is compatible with the body lumen in which they are implanted. The stent should preferably be configured so that there is a substantial amount of open area and preferably the open area to metal ratio is at least 80 percent. The stent should also be configured so that dissections or flaps in the body lumen wall are covered and tacked up by the stent.


Referring to FIGS. 1, 2, and 4, in a preferred embodiment, a stent 10 of the present invention is formed partially or completely of alloys such as nitinol (NiTi) which have superelastic (SE) characteristics. Stent 10 is somewhat similar to the stent disclosed in U.S. Pat. No. 5,569,295, “Expandable Stents and Method for Making Same,” issued to Lam on Oct. 29, 1996, which patent is incorporated herein by reference. Some differences of the present invention stent from that disclosed in the '295 patent is that the present invention stent is preferably constructed of a superelastic material with the addition of a ternary element, and the strut pattern has changed. Of course, the configuration of the stent 10 is just one example of many stent configurations that are contemplated by the present invention.


Turning to FIG. 4, stent 10 has a tubular form which preferably includes a plurality of radially expandable cylindrical elements 24 disposed generally coaxially and interconnected by members 26 disposed between adjacent cylindrical elements 24. The shapes of the struts 12 forming the strut pattern are designed so they can preferably be nested. This strut pattern is best seen from the flattened plan view of FIG. 4. The serpentine patterned struts 12 are nested such that the extended portions of the struts of one cylindrical element 24 intrude into a complementary space within the circumference of an adjacent cylindrical element. In this manner, the plurality of cylindrical elements 24 can be more tightly packed lengthwise.


As introduced above, an exemplary stent of the present invention includes a superelastic material. In a general sense, superelasticity implies that the material can undergo a large degree of reversible strain as compared to common steel. In a technical sense, the term “superelasticity” and sometimes “pseudoelasticity” refer to an isothermal transformation in nitinol. More specifically, it refers to stress inducing a martensitic phase from an austenitic phase. Alloys having superelastic properties generally have at least two phases: a martensitic phase, which has a relatively low tensile strength and which is stable at relatively low temperatures, and an austenitic phase, which has a relatively high tensile strength and which is stable at temperatures higher than the martensitic phase. Superelastic characteristics generally allow the metal stent to be deformed by collapsing the stent and creating stress which causes the NiTi to reversibly change to the martensitic phase. The stent is restrained in the deformed condition inside a delivery sheath typically to facilitate the insertion into a patient's body, with such deformation causing the isothermal phase transformation. Once within the body lumen, the restraint on the stent is removed, thereby reducing the stress thereon so that the superelastic stent returns towards its original undeformed shape through isothermal transformation back to the austenitic phase. Under these conditions, the stent can be described as self-expanding.


Returning to FIG. 1, the graphic illustrates, in a partial cross-sectional view, the distal end of a rapid exchange stent delivery system that includes a guide wire 14, a delivery sheath 16, and an intravascular catheter 18. For the sake of clarity, the illustration of the delivery system in FIG. 1 has been simplified. It is just one example of a delivery system that may be used with the present invention. More details of a delivery system specifically for use with a self-expanding stent may be found in, for example, U.S. Pat. No. 6,077,295 to Limon et al., entitled “Self-Expanding Stent Delivery System,” which is incorporated herein by reference. Other delivery systems such as over-the-wire may be used without departing from the scope of the instant invention.



FIG. 1 further shows an optional expandable balloon 20 inflated through an inflation lumen (not shown), although the balloon is typically not needed for a self-expanding stent. The stent 10 is first crimped on to the deflated balloon 20, and the entire assembly is kept underneath the delivery sheath 16 until the moment the stent 10 is deployed. The stent 10 is self-expanding so that when the sheath 16 is withdrawn, the stent 10 expands to its larger deployment diameter without assistance from the balloon 20. Nevertheless, some procedures specifically use the balloon 20 to further expand the stent 10 for improved seating in the artery wall 29.



FIG. 2 illustrates the self-expanding stent 10 in the expanded condition after the delivery system has been removed. If an external force is applied to the artery 28, the expanded stent 10 temporarily and at least partially collapses or deforms. As the stent 10 deforms, stress in the nickel-titanium alloy causes an isothermal phase transformation from the austenitic phase to the martensitic phase. When the external force is removed, the stress in stent 10 is likewise diminished so that the stent quickly transforms back from the martensitic phase to the austenitic phase. As this almost instantaneous, isothermal transformation occurs, the stent 10 returns to its fully expanded state and the artery remains open. When the superelastic stent 10 is implanted in an artery 28, its high resilience effectively maintains the patency of the artery while minimizing the risk of permanent arterial collapse at the implant site if the stent is temporarily deformed due to external forces. Furthermore, the resilience of the stent 10 supports the flap 30 to maintain patency of the artery.


Stent 10 is preferably formed from a superelastic material such as nickel-titanium and undergoes an isothermal transformation when stressed if in the austenitic phase. For most purposes, the transformation temperature for the stent 10 is preferably set low enough such that the nickel-titanium alloy is in the austenitic phase while at body temperature.


According to theory, when stress is applied to a specimen of a metal such as nitinol exhibiting superelastic characteristics at a temperature at or above that which the transformation of the martensitic phase to the austenitic phase is complete, the specimen deforms elastically until it reaches a particular stress level where the alloy then undergoes a stress-induced phase transformation from the austenitic phase to the martensitic phase. As the phase transformation progresses, the alloy undergoes significant increases in strain with little or no corresponding increases in stress. The strain increases while the stress remains essentially constant until the transformation of the austenitic phase to the martensitic phase is complete. Thereafter, further increase in stress is necessary to cause further deformation. The martensitic metal first yields elastically upon the application of additional stress and then plastically with permanent residual deformation.


If the load on the specimen is removed before any permanent deformation has occurred, the stress-induced martensite elastically recovers and transforms back to the austenitic phase. The reduction in stress first causes a decrease in strain. As stress reduction reaches the level at which the martensitic phase begins to transform back into the austenitic phase, the stress level in the specimen remains essentially constant (but less than the constant stress level at which the austenitic crystalline structure transforms to the martensitic crystalline structure until the transformation back to the austenitic phase is complete); i.e., there is significant recovery in strain with only negligible corresponding stress reduction. After the transformation back to austenite is complete, further stress reduction results in elastic strain reduction. This ability to incur significant strain at relatively constant stress upon the application of a load and to recover from the deformation upon the removal of the load is commonly referred to as “superelasticity” and sometimes “pseudoelasticity.”



FIG. 3 illustrates an idealized stress-strain hysteresis curve for a superelastic, binary nickel-titanium alloy. The relationship is plotted on x-y axes, with the x axis representing strain and the y axis representing stress. For ease of illustration, the x-y axes are labeled on a scale typical for superelastic nitinol, with stress from 0 to 60 ksi and strain from 0 to 9 percent, respectively.


Looking at the plot in FIG. 3, the line from point A to point B represents the elastic deformation of the nickel-titanium alloy. After point B the strain or deformation is no longer proportional to the applied stress and it is in the region between point B and point C that the stress-induced transformation of the austenitic phase to the martensitic phase begins to occur.


At point C moving toward point D, the material enters a region of relatively constant stress with significant deformation or strain. This constant or plateau region is known as the loading stress, since it represents the behavior of the material as it encounters continuous increasing strain. It is in this plateau region C-D that the transformation from austenite to martensite occurs.


At point D the transformation to the martensitic phase due to the application of stress to the specimen is substantially complete. Beyond point D the martensitic phase begins to deform, elastically at first, but, beyond point E, the deformation is plastic or permanent.


When the stress applied to the superelastic metal is removed, the material behavior follows the curve from point E to point F. Within the E to F region, the martensite recovers its original shape, provided that there was no permanent deformation to the martensitic structure. At point F in the recovery process, the metal begins to transform from the stress-induced, unstable, martensitic phase back to the more stable austenitic phase.


In the region from point G to point H, which is also an essentially constant or plateau stress region, the phase transformation from martensite back to austenite takes place. This constant or plateau region G-H is known as the unloading stress. The line from point I to the starting point A represents the elastic recovery of the metal to its original shape.


Binary nickel-titanium alloys that exhibit superelasticity have an unusual stress-strain relationship as just described and as plotted in the curve of FIG. 3. As emphasized above, the superelastic curve is characterized by regions of nearly constant stress upon loading, identified above as loading plateau stress C-D and unloading plateau stress G-H. Naturally, the loading plateau stress C-D always has a greater magnitude than the unloading plateau stress G-H. The loading plateau stress represents the period during which martensite is being stress-induced in favor of the original austenitic crystalline structure. As the load is removed, the stress-induced martensite transforms back into austenite along the unloading plateau stress part of the curve. The difference in stress between the stress at loading C-D and unloading stress G-H defines the hysteresis of the system.


The present invention seeks to preserve the superelastic qualities of nickel-titanium alloys just described yet improve upon the material's radiopacity by addition of a ternary element. This is preferably accomplished in one embodiment by forming a composition consisting essentially of about 30 to about 52 percent titanium and the balance nickel and up to 10 percent of one or more additional ternary alloying elements. Such ternary alloying elements may be selected from the group consisting of iridium, platinum, gold, rhenium, tungsten, palladium, rhodium, tantalum, silver, ruthenium, or hafnium. In the preferred embodiment, the atomic percentage of platinum is greater than or equal to 2.5 and less than or equal to 15. In an alternative embodiment, the atomic percentage of palladium is greater than or equal to 2.5 and less than or equal to 20.


A preferred embodiment stent according to the present invention has 42.8 atomic percent nickel, 49.7 atomic percent titanium, and 7.5 atomic percent platinum. Through empirical studies, the aforementioned compositions produce stent patterns having a radiopacity comparable to the same size and pattern stent made from 316 L stainless steel with a 2.7 to 6.5 μm gold coating.


In various alternative embodiments, the present invention contemplates the minor addition of a quaternary element, for example, iron, to further enhance the alloy's formability or its thermomechanical properties. The presence of impurities such as carbon or oxygen or the like in the present invention alloy is also possible.


A preferred method of fabricating the present invention superelastic, radiopaque metallic stent entails first fashioning nickel-titanium tubing. The tubing is made from vacuum induction melting nickel and titanium with the ternary element according to the compositions suggested above. The ingot is then remelted for consistency. The ingot is next hot rolled into bar stock, then straightened and sized, and hot or cold formed into a cylinder. The cylinder is gun drilled to form the tubing. Instead of gun drilling, other methods of material removal known in the art may be used, including electric discharge machining (EDM), laser beam machining, and the like. Next, the tubing is cold drawn and annealed repeatedly to achieve the finished dimensions.


Any of the foregoing preferred embodiment steps may be repeated, taken out of sequence, or omitted as necessary depending on desired results. From here on, the tubing follows conventional stent fabrication techniques such as laser cutting the strut pattern, heat setting, etc.


The following are additional processing guide posts for the present invention to achieve a sufficiently radiopaque stent yet maintaining the superelastic stress-strain behavior of the alloy. Empirical evidence suggests that, in various preferred embodiments, a Ni—Ti—Pd or Ni—Ti—Pt ingot should have the following austenite finish temperature: 0 degrees C.≦Af≦40 degrees C. The Ni—Ti—Pd or Ni—Ti—Pt tubing should exhibit an austenite finish temperature of: −15 degrees C.≦Af≦15 degrees C. In an exemplary embodiment, the final laser cut Ni—Ti—Pd or Ni—Ti—Pt stent should exhibit an austenite finish temperature of: 0 degrees C.≦Af≦37 degrees C. Of course, the Af of the finished laser cut stent can be set as needed by various heat treating processes known in the art.


It is understood that the austenite finish temperature (Af) is defined to mean the temperature at which the material completely reverts to austenite. In technical terms, the Af (and other transformation temperatures As, Ms, Mf) as it applies to an ingot made of Ni—Ti—Pd or Ni—Ti—Pt, for example, is determined by a Differential Scanning Calorimeter (DSC) test, known in the art. The DSC test method to determine transformation temperatures for the ingot is guided by ASTM standard no. F 2004-00, titled “Standard Test Method For Transformation Temperature Of Nickel-Titanium Alloys By Thermal Analysis.”


The “active Af” for the tubing and the finished stent is determined by a bend and free recovery test, also known in the art. In such a test, the tubing is cooled to under the Mf temperature, deformed, and warmed up. While monitoring the increasing temperature, the point of final recovery of the deformation in the tubing approximates the Af of the material. The active Af testing technique is guided by a second ASTM standard entitled “Standard Test Method For Determination Of Transformation Temperature Of Nickel-Titanium Shape Memory Alloys By Bend And Free Recovery,” or by equivalent test methods known in the art.


Samples of wire made in accordance with the foregoing exemplary embodiments were tested. Specifically, the stress-strain relationship based on empirical data for nickel-titanium-palladium and nickel-titanium-platinum are plotted against binary nitinol in FIG. 5. Curve A corresponds to a sample of nickel-titanium-platinum. Curve B is based on a sample of binary nitinol. Curve C is based on a sample of nickel-titanium-palladium. To generate the empirical data, the wire samples were placed under increasing tension until past the phase transformation from their initial austenitic phase to their martensitic phase. Tension was then slowly released prior to any plastic deformation until stress on the samples dropped to zero with full deformation recovery.


As is apparent from the plot of FIG. 5, the present invention nickel-titanium-palladium and nickel-titanium-platinum alloys have stress-strain curves that closely follow the hysteresis curve for binary nitinol. All three curves have essentially flat loading and unloading plateau stresses indicating the presence of a phase transformation that is characteristic of superelastic metals. Hence, the present invention nitinol stent incorporates a ternary element, in these exemplary embodiments palladium or platinum, to improve radiopacity yet the materials' superelastic capability is preserved. What has been missing heretofor is empirical evidence that this level of radiopacity can be achieved while preserving the superelastic characteristics of these alloys.


The present invention further provides a nitinol stent having improved radiopacity without reliance on increasing the stent wall thickness or strut thickness. Increasing wall or strut thicknesses detracts from the flexibility of the stent, which is detrimental to deliverability. Rather, the present invention superelastic nitinol stent has a thin wall/strut thickness and/or strut cross-sectional area akin to a conventional stainless steel stent, and has comparable radiopacity to a stainless steel stent with a thin coating of gold. The wall/strut thickness is defined by the difference between the inside diameter and the outside diameter of the tube.


Indeed, the improved radiopacity of the present invention stent can be characterized strictly by strut thickness. In this con, the present invention radiopaque stent has a reduced strut thickness yet exhibits the radiopacity of an identical stent having thicker struts. In other words, given a stent exhibiting a certain level of radiopacity, the present invention stent having the identical dimensions and strut pattern achieves that level of radiopacity yet it has at least a 10 percent reduction in strut thickness as compared to the reference stent.


Alternatively, the 10 percent reduction can also be quantified in terms of the cross-sectional area of the strut. That is, for a given stent having a certain level of radiopacity with struts with a given cross-sectional area, the present invention stent having the same dimensions and strut pattern achieves the same level of radiopacity but has struts with at least a 10 percent reduction in cross-sectional area as compared to the reference stent.


Another aspect of nitinol aside from its superelasticity is shape memory. The present invention can also be employed with respect to this physical attribute as described below.


The shape memory effect allows a nitinol structure to be deformed to facilitate its insertion into a body lumen or cavity, and then heated within the body so that the structure returns to its original, set shape. Nitinol alloys having shape memory effect generally have at least two phases: a martensitic phase, which has a relatively low tensile strength and which is stable at relatively low temperatures, and an austenitic phase, which has a relatively high tensile strength and which is stable at temperatures higher than the martensitic phase.


Shape memory effect is imparted to the alloy by heating the nickel-titanium metal to a temperature above which the transformation from the martensitic phase to the austenitic phase is complete; i.e., a temperature above which the austenitic phase is stable. The shape of the metal during this heat treatment is the shape “remembered.” The heat-treated metal is cooled to a temperature at which the martensitic phase is stable, causing the austenitic phase to transform to the martensitic phase. The metal in the martensitic phase is then plastically deformed, e.g., to facilitate the entry thereof into a patient's body. Subsequent heating of the deformed martensitic phase to a temperature above the martensite to austenite transformation temperature causes the deformed martensitic phase to transform to the austenitic phase. During this phase transformation the metal reverts back towards its original shape.


The recovery or transition temperature may be altered by making minor variations in the composition of the metal and in processing the material. In developing the correct composition, biological temperature compatibility must be determined in order to select the correct transition temperature. In other words, when the stent is heated, it must not be so hot that it is incompatible with the surrounding body tissue. Other shape memory materials may also be utilized, such as, but not limited to, irradiated memory polymers such as autocrosslinkable high density polyethylene (HDPEX). Shape memory alloys are known in the art and are discussed in, for example, “Shape Memory Alloys,” Scientific American Vol. 281, pp. 74-82 (November 1979), incorporated herein by reference.


Shape memory alloys undergo a transition between an austenitic phase and a martensitic phase at certain temperatures. When they are deformed while in the martensitic phase, they retain this deformation as long as they remain in the same phase, but revert to their original configuration when they are heated to a transition temperature, at which time they transform to their austenitic phase. The temperatures at which these transitions occur are affected by the nature of the alloy and the condition of the material. Nickel-titanium-based alloys (NiTi), wherein the transition temperature is slightly lower than body temperature, are preferred for the present invention. It is desirable to have the transition temperature set at just below body temperature to insure a rapid transition from the martensitic state to the austenitic state when the stent is implanted in a body lumen.


Turning again to FIGS. 1, 2, and 4, the present invention stent 10 is formed from a shape memory alloy, such as NiTi discussed above. After the stent 10 is inserted into an artery 28 or other vessel, the delivery sheath 16 is withdrawn exposing the stent 10 to the ambient environment. The stent 10 then immediately expands due to contact with the higher temperature within artery 28 as described for devices made from shape memory alloys. An optional expandable balloon 20 may be inflated by conventional means to further expand the stent 10 radially outward.


Again, if an external force is exerted on the artery, the stent 10 temporarily at least partially collapses. But the stent 10 then quickly regains its former expanded shape due to its shape memory qualities. Thus, a crush-resistant stent, having shape memory characteristics, is implanted in a vessel. It maintains the patency of a vessel while minimizing both the risk of permanent vessel collapse and the risk of dislodgment of the stent from the implant site if the stent is temporarily deformed due to external forces.


When the stent 10 is made in accordance with the present invention, it is also highly radiopaque. The same alloying processes described earlier are used here to add the ternary element to increase the radiopacity of the stent. Insofar as the martensitic to austenitic phase transformation is thermally driven, the deployment of the present invention stent can be explained in terms of the shape memory effect.


While the present invention has been illustrated and described herein in terms of a radiopaque nitinol stent, it is apparent to those skilled in the art that the present invention can be used in other instances. Other modifications and improvements may be made without departing from the scope of the present invention.

Claims
  • 1. A method for providing radiopaque tubing, comprising: forming a tubular-shaped body having a thin wall, wherein the body includes a superelastic nickel-titanium alloy and the alloy further includes a ternary element selected from the group of chemical elements consisting of iridium, platinum, gold, rhenium, tungsten, palladium, rhodium, tantalum, silver, ruthenium, and hafnium;wherein forming a tubular-shaped body includes melting nickel, titanium, and the ternary element, cooling to form an alloy ingot, hot forming the alloy ingot, forming the alloy ingot into a cylinder, drilling the cylinder to form tubing, drawing the tubing, and annealing the tubing.
  • 2. The method of claim 1, wherein the ternary element is platinum, and the atomic percent of platinum is greater than 3 and less than or equal to 15.
  • 3. The method of claim 1, wherein the ternary element is palladium, and the atomic percent of palladium is greater than 3 and less than or equal to 20.
CROSS-REFERENCE TO RELATED APPLICATIONS

This is a divisional of application Ser. No. 10/900,632, filed Jul. 27, 2004, which is a continuation of Ser. No. 09/752,212, filed Dec. 27, 2000, now U.S. Pat. No. 6,855,161, all of which are incorporated herein by reference.

US Referenced Citations (286)
Number Name Date Kind
2738294 Spence Mar 1956 A
2768271 Meredith Oct 1956 A
3558369 Wang et al. Jan 1971 A
3605725 Bentov Sep 1971 A
3620212 Fannon et al. Nov 1971 A
3753700 Harrison et al. Aug 1973 A
3890977 Wilson Jun 1975 A
3953253 Clark Apr 1976 A
4019899 Negishi et al. Apr 1977 A
4037324 Andreasen Jul 1977 A
4069226 Kablaoui et al. Jan 1978 A
4144057 Melton et al. Mar 1979 A
4233690 Akins Nov 1980 A
4283233 Goldstein et al. Aug 1981 A
4304613 Wang et al. Dec 1981 A
4310354 Fountain et al. Jan 1982 A
4323071 Simpson et al. Apr 1982 A
4386971 Melton et al. Jun 1983 A
4390599 Broyles Jun 1983 A
4411655 Schreck Oct 1983 A
4425908 Simon Jan 1984 A
4427000 Ueda Jan 1984 A
4439185 Lundquist Mar 1984 A
4503569 Dotter Mar 1985 A
4505767 Quin Mar 1985 A
4512338 Balko et al. Apr 1985 A
4516972 Samson May 1985 A
4518444 Albrecht et al. May 1985 A
4533411 Melton Aug 1985 A
4538622 Samson et al. Sep 1985 A
4554929 Samson et al. Nov 1985 A
4565589 Harrison Jan 1986 A
4580568 Gianturco Apr 1986 A
4582181 Samson Apr 1986 A
4616652 Simpson Oct 1986 A
4631094 Simpson et al. Dec 1986 A
4638805 Powell Jan 1987 A
4665906 Jervis May 1987 A
4740253 Simpson et al. Apr 1988 A
4748986 Morrison et al. Jun 1988 A
4768507 Fischell et al. Sep 1988 A
4770725 Simpson et al. Sep 1988 A
4776844 Ueda Oct 1988 A
4793350 Mar et al. Dec 1988 A
4827941 Taylor et al. May 1989 A
4846573 Taylor et al. Jul 1989 A
4856516 Hillstead Aug 1989 A
4865663 Tuominen et al. Sep 1989 A
4875489 Messner et al. Oct 1989 A
4881981 Thoma et al. Nov 1989 A
4894100 Yamauchi et al. Jan 1990 A
4925445 Sakamoto et al. May 1990 A
4935068 Duerig Jun 1990 A
4943326 Ozawa et al. Jul 1990 A
4969890 Sugita et al. Nov 1990 A
4984581 Stice Jan 1991 A
4991602 Amplatz et al. Feb 1991 A
5001446 Tsuji et al. Mar 1991 A
5002563 Pyka et al. Mar 1991 A
5025799 Wilson Jun 1991 A
5044947 Sachdeva et al. Sep 1991 A
5067489 Lind Nov 1991 A
5067957 Jervis Nov 1991 A
5069226 Yamauchi et al. Dec 1991 A
5092877 Pinchuk Mar 1992 A
5108523 Peterseim et al. Apr 1992 A
5114504 AbuJudom, II et al. May 1992 A
5117838 Palmer et al. Jun 1992 A
5120308 Hess Jun 1992 A
5135503 Abrams Aug 1992 A
5143085 Wilson Sep 1992 A
5171383 Sagaye et al. Dec 1992 A
5188621 Samson Feb 1993 A
5190546 Jervis Mar 1993 A
5201901 Harada et al. Apr 1993 A
5230348 Ishibe et al. Jul 1993 A
5230349 Langberg Jul 1993 A
5234458 Metais Aug 1993 A
5238004 Sahatjian et al. Aug 1993 A
5243996 Hall Sep 1993 A
5271975 Solano Dec 1993 A
5292331 Boneau Mar 1994 A
5318527 Hyde et al. Jun 1994 A
5341815 Cofone et al. Aug 1994 A
5341818 Abrams et al. Aug 1994 A
5345937 Middleman et al. Sep 1994 A
5345945 Hodgson et al. Sep 1994 A
5350398 Pavcnik et al. Sep 1994 A
5350419 Bendel et al. Sep 1994 A
5354623 Hall Oct 1994 A
5368049 Raman et al. Nov 1994 A
5411476 Abrams et al. May 1995 A
5458615 Klemm et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5486183 Middleman et al. Jan 1996 A
5507766 Kugo et al. Apr 1996 A
5509923 Middleman et al. Apr 1996 A
5514154 Lau et al. May 1996 A
5534007 St. Germain et al. Jul 1996 A
5549626 Miller et al. Aug 1996 A
5562641 Flomenblit et al. Oct 1996 A
5569295 Lam Oct 1996 A
5573520 Schwartz et al. Nov 1996 A
5597378 Jervis Jan 1997 A
5607444 Lam Mar 1997 A
5611874 Zadno-Azizi et al. Mar 1997 A
5630840 Mayer May 1997 A
5632746 Middleman et al. May 1997 A
5637089 Abrams et al. Jun 1997 A
5641364 Golberg et al. Jun 1997 A
5643312 Fischell et al. Jul 1997 A
5667522 Flomenblit et al. Sep 1997 A
5690644 Yurek et al. Nov 1997 A
5695111 Nanis et al. Dec 1997 A
5713853 Clark et al. Feb 1998 A
5720300 Fagan et al. Feb 1998 A
5720754 Middleman et al. Feb 1998 A
5749370 Brooks et al. May 1998 A
5749870 Gloth et al. May 1998 A
5749879 Middleman et al. May 1998 A
5759192 Saunders Jun 1998 A
5766218 Arnott Jun 1998 A
5776114 Frantzen et al. Jul 1998 A
5780807 Saunders Jul 1998 A
5810874 Lefebvre Sep 1998 A
5820628 Middleman et al. Oct 1998 A
5833631 Nguyen Nov 1998 A
5836966 St. Germain Nov 1998 A
5836968 Simon et al. Nov 1998 A
5837313 Ding et al. Nov 1998 A
5843244 Pelton et al. Dec 1998 A
5865768 Orr Feb 1999 A
5876356 Viera et al. Mar 1999 A
5876434 Flomenblit et al. Mar 1999 A
5885381 Mitose et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5902317 Kleshinski et al. May 1999 A
5904690 Middleman et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5922393 Jayaraman Jul 1999 A
5927345 Samson Jul 1999 A
5931819 Fariabi Aug 1999 A
5951793 Mitose et al. Sep 1999 A
5964770 Flomenblit et al. Oct 1999 A
5976153 Fischell et al. Nov 1999 A
5980471 Jafari Nov 1999 A
5980566 Alt et al. Nov 1999 A
5989280 Euteneuer et al. Nov 1999 A
6001123 Lau Dec 1999 A
6004330 Middleman et al. Dec 1999 A
6004629 Madigan Dec 1999 A
6007558 Ravenscroft et al. Dec 1999 A
RE36628 Sagae et al. Mar 2000 E
6051021 Frid Apr 2000 A
6053992 Wu et al. Apr 2000 A
6059738 Stoltze et al. May 2000 A
6059810 Brown et al. May 2000 A
6066149 Samson et al. May 2000 A
6068610 Ellis et al. May 2000 A
6068623 Zadno-Azizi et al. May 2000 A
6077287 Taylor et al. Jun 2000 A
6077295 Limon et al. Jun 2000 A
6086610 Duerig et al. Jul 2000 A
6096175 Roth Aug 2000 A
6099549 Bosma et al. Aug 2000 A
6106642 DiCarlo et al. Aug 2000 A
6129739 Khosravi Oct 2000 A
6131266 Saunders Oct 2000 A
6137060 Avellanet Oct 2000 A
6152946 Broome et al. Nov 2000 A
6165140 Ferrera Dec 2000 A
6165195 Wilson et al. Dec 2000 A
6165292 Abrams et al. Dec 2000 A
6168571 Solar et al. Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6171334 Cox Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6183409 Armini Feb 2001 B1
6190332 Muni et al. Feb 2001 B1
6210312 Nagy Apr 2001 B1
6217567 Zadno-Azizi et al. Apr 2001 B1
6217589 McAlister Apr 2001 B1
6245103 Stinson Jun 2001 B1
6257513 Cockerham et al. Jul 2001 B1
6264671 Stack et al. Jul 2001 B1
6277139 Levinson et al. Aug 2001 B1
6280539 Abrams et al. Aug 2001 B1
6287336 Globerman et al. Sep 2001 B1
6306141 Jervis Oct 2001 B1
6312454 Stockel et al. Nov 2001 B1
6312455 Duerig et al. Nov 2001 B2
6322847 Zhong et al. Nov 2001 B1
6325824 Limon Dec 2001 B2
6329069 Azizi et al. Dec 2001 B1
6346116 Brooks et al. Feb 2002 B1
6352515 Anderson et al. Mar 2002 B1
6358556 Ding et al. Mar 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6375458 Moorleghem et al. Apr 2002 B1
6375628 Zadno-Azizi et al. Apr 2002 B1
6375629 Muni et al. Apr 2002 B1
6379369 Abrams et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6390993 Cornish et al. May 2002 B1
6391502 Anderson et al. May 2002 B1
6402761 McAlister Jun 2002 B2
6419692 Yang et al. Jul 2002 B1
6419693 Fariabi Jul 2002 B1
6428634 Besselink et al. Aug 2002 B1
6432116 Callister et al. Aug 2002 B1
6447523 Middleman et al. Sep 2002 B1
6451047 McCrea et al. Sep 2002 B2
6451052 Burmeister et al. Sep 2002 B1
6458145 Ravenscroft et al. Oct 2002 B1
6461453 Abrams et al. Oct 2002 B1
6468230 Muni et al. Oct 2002 B2
6500182 Foster Dec 2002 B2
6508803 Horikawa et al. Jan 2003 B1
6509094 Shah et al. Jan 2003 B1
6533805 Jervis Mar 2003 B1
6551341 Boylan et al. Apr 2003 B2
6554848 Boylan et al. Apr 2003 B2
6558405 McInnes May 2003 B1
6572646 Boylan et al. Jun 2003 B1
6582461 Burmeister et al. Jun 2003 B1
6592559 Pakter et al. Jul 2003 B1
6592570 Abrams et al. Jul 2003 B2
6602208 Jafari Aug 2003 B2
6602228 Nanis et al. Aug 2003 B2
6602272 Boylan et al. Aug 2003 B2
6626937 Cox Sep 2003 B1
6638372 Abrams Oct 2003 B1
6682608 Abrams et al. Jan 2004 B2
6706053 Boylan et al. Mar 2004 B1
6755845 Kieturakis et al. Jun 2004 B2
6755855 Yurek et al. Jun 2004 B2
6824560 Pelton Nov 2004 B2
6830638 Boylan et al. Dec 2004 B2
7037320 Brady et al. May 2006 B2
7128757 Boylan et al. Oct 2006 B2
7175655 Molaei Feb 2007 B1
7244319 Abrams et al. Jul 2007 B2
7258753 Abrams et al. Aug 2007 B2
20010007953 Duerig et al. Jul 2001 A1
20010039446 Edwin et al. Nov 2001 A1
20010039449 Johnson et al. Nov 2001 A1
20010047202 Slaikeu et al. Nov 2001 A1
20010049549 Boylan et al. Dec 2001 A1
20020010481 Jayaraman et al. Jan 2002 A1
20020046785 Abrams et al. Apr 2002 A1
20020052627 Boylan et al. May 2002 A1
20020062092 Muni et al. May 2002 A1
20020068954 Foster Jun 2002 A1
20020082681 Boylan et al. Jun 2002 A1
20020087099 Nanis et al. Jul 2002 A1
20020121316 Abrams et al. Sep 2002 A1
20020138129 Armstrong et al. Sep 2002 A1
20020193827 McGuckin, Jr. et al. Dec 2002 A1
20030004536 Boylan et al. Jan 2003 A1
20030036794 Ragheb et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030055449 Lee et al. Mar 2003 A1
20030055484 Lau et al. Mar 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030069521 Reynolds et al. Apr 2003 A1
20030120181 Toma et al. Jun 2003 A1
20030127158 Abrams et al. Jul 2003 A1
20030158575 Boylan et al. Aug 2003 A1
20030199920 Boylan et al. Oct 2003 A1
20040084115 Abrams et al. May 2004 A1
20040093009 Denison et al. May 2004 A1
20040158281 Boylan et al. Aug 2004 A1
20040172055 Huter et al. Sep 2004 A1
20040220608 D'Aquanni et al. Nov 2004 A1
20040249447 Boylan et al. Dec 2004 A1
20050038500 Boylan et al. Feb 2005 A1
20060086440 Boylan et al. Apr 2006 A1
20060212068 Boylan Sep 2006 A1
20070233179 Brady et al. Oct 2007 A1
20070239259 Boylan Oct 2007 A1
20070249965 Abrams et al. Oct 2007 A1
20090098013 Boylan et al. Apr 2009 A1
20090248130 Boylan Oct 2009 A1
20100125329 Lin et al. May 2010 A1
Foreign Referenced Citations (87)
Number Date Country
0145166 Jun 1985 EP
0199715 Oct 1986 EP
0340304 Nov 1989 EP
0395098 Oct 1990 EP
0480427 Apr 1992 EP
0484805 May 1992 EP
0491349 Jun 1992 EP
0491349 Jun 1992 EP
0491349 Jun 1992 EP
0491349 Jun 1992 EP
0515078 Nov 1992 EP
0520073 Dec 1992 EP
0550258 Jul 1993 EP
0550288 Jul 1993 EP
0569166 Nov 1993 EP
0791340 Aug 1997 EP
0804934 Nov 1997 EP
0806220 Nov 1997 EP
0812928 Dec 1997 EP
0815803 Jan 1998 EP
0 873 734 Oct 1998 EP
0879614 Nov 1998 EP
0968688 Jan 2000 EP
1027906 Aug 2000 EP
1426071 Jun 2004 EP
44-31704 Dec 1969 JP
44-32286 Dec 1969 JP
53-12759 Feb 1978 JP
55-164304 Dec 1980 JP
57-89859 Jun 1982 JP
58-161746 Sep 1983 JP
60-145155 Jul 1985 JP
60-138547 Sep 1985 JP
60-248856 Dec 1985 JP
61-84361 Apr 1986 JP
61-183455 Aug 1986 JP
62-199757 Sep 1987 JP
62-199758 Sep 1987 JP
62-235449 Oct 1987 JP
63-171570 Jul 1988 JP
64-49571 Feb 1989 JP
1-124473 May 1989 JP
1-242763 Sep 1989 JP
2252467 Oct 1990 JP
2289265 Nov 1990 JP
2289266 Nov 1990 JP
4-9162 Jan 1992 JP
50-19512 Jan 1993 JP
5-092044 Apr 1993 JP
6-83726 Mar 1994 JP
61-08431 Apr 1994 JP
09-215753 Aug 1997 JP
11-76420 Mar 1999 JP
2000-140124 May 2000 JP
03-295562 Oct 2003 JP
4-292174 Oct 2004 JP
WO 8910088 Nov 1989 WO
WO 8912175 Dec 1989 WO
WO 9013329 Nov 1990 WO
WO 9115152 Oct 1991 WO
WO 9205828 Apr 1992 WO
WO 9319803 Oct 1993 WO
WO 9519800 Jul 1995 WO
WO 9724978 Jul 1997 WO
WO 9738747 Oct 1997 WO
WO 9820801 May 1998 WO
WO 9820810 May 1998 WO
WO 9932051 Jul 1999 WO
WO 9944542 Sep 1999 WO
WO 0004846 Feb 2000 WO
WO 0049970 Aug 2000 WO
WO 0067665 Nov 2000 WO
WO 0067668 Nov 2000 WO
WO 0069359 Nov 2000 WO
WO 0139695 Jun 2001 WO
WO 0141859 Jun 2001 WO
WO 0182830 Nov 2001 WO
WO 0236841 May 2002 WO
WO 02051462 Jul 2002 WO
WO 02102281 Dec 2002 WO
WO 03002166 Jan 2003 WO
WO 03028796 Apr 2003 WO
WO 03097148 Nov 2003 WO
WO 2004033016 Apr 2004 WO
WO 2004098458 Nov 2004 WO
WO 2005102407 Nov 2005 WO
WO 2006081011 Aug 2006 WO
Related Publications (1)
Number Date Country
20080027532 A1 Jan 2008 US
Divisions (1)
Number Date Country
Parent 10900632 Jul 2004 US
Child 11870262 US
Continuations (1)
Number Date Country
Parent 09752212 Dec 2000 US
Child 10900632 US